Study of CHS-114 in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Advanced Solid TumorHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

CHS-114

CHS-114

DRUG

toripalimab

toripalimab-tpzi

Trial Locations (16)

21201

RECRUITING

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore

30308

RECRUITING

Emory Winship Cancer Institute, Atlanta

32827

RECRUITING

SCRI Lake Nona DDU (FL Cancer Specialists), Orlando

37203

RECRUITING

Vanderbilt-Ingram Cancer Center, Nashville

40202

RECRUITING

University of Louisville, Louisville

45219

RECRUITING

University of Cincinnati, Cincinnati

48104

RECRUITING

University of Michigan, Ann Arbor

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center, Detroit

60521

RECRUITING

Hope & Healing Cancer Services, Hinsdale

63110

RECRUITING

Washington University, St Louis

78229

RECRUITING

START- San Antonio, San Antonio

84119

RECRUITING

START Mountain, West Valley City

92663

RECRUITING

Hoag Memorial Hospital, Newport Beach

93030

RECRUITING

FOMAT Medical Research, Oxnard

94305

RECRUITING

Stanford Cancer Center, Palo Alto

98109

RECRUITING

University of Washington/Fred Hutchinson Cancer Center, Seattle

Sponsors
All Listed Sponsors
lead

Coherus Oncology, Inc.

INDUSTRY

NCT05635643 - Study of CHS-114 in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter